Use of sodium –glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry

ConclusionIn a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.

Source: European Journal of Heart Failure - March 3, 2021 Category: Cardiology Authors: Peter M. Becher, Benedikt Schrage, Giulia Ferrannini, Lina Benson, Javed Butler, Juan Jesus Carrero, Francesco Cosentino, Ulf Dahlstr öm, Linda Mellbin, Giuseppe M.C. Rosano, Gianfranco Sinagra, Davide Stolfo, Lars H. Lund, Gianluigi Savares Tags: Research Article Source Type: research